HC Wainwright Analysts Increase Earnings Estimates for ACRS

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – HC Wainwright boosted their Q1 2026 earnings per share estimates for Aclaris Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.14) for the quarter, up from their prior estimate of ($0.15). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.50) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%.The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $2.07 million.

A number of other research analysts have also weighed in on the stock. Wall Street Zen lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Craig Hallum assumed coverage on shares of Aclaris Therapeutics in a research report on Friday, January 30th. They set a “buy” rating and a $10.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.80.

Aclaris Therapeutics Trading Down 1.3%

Shares of ACRS stock opened at $3.69 on Monday. The firm has a market capitalization of $445.01 million, a PE ratio of -6.96 and a beta of 0.88. The firm has a fifty day simple moving average of $3.41 and a two-hundred day simple moving average of $2.78. Aclaris Therapeutics has a 12 month low of $1.05 and a 12 month high of $4.89.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. ProShare Advisors LLC bought a new stake in Aclaris Therapeutics during the second quarter worth $26,000. AXQ Capital LP bought a new position in Aclaris Therapeutics in the 3rd quarter valued at $27,000. Police & Firemen s Retirement System of New Jersey bought a new position in Aclaris Therapeutics in the 2nd quarter valued at $28,000. XTX Topco Ltd purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter valued at $34,000. Finally, R Squared Ltd purchased a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at $37,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics News Summary

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $16 price target and raised FY2026 and FY2027 EPS forecasts (FY2026 to ($0.48) from ($0.52); FY2027 to ($0.50) from ($0.55)), implying meaningful upside vs. the current share price and signaling the analyst sees improving financial trends. Article Title
• Positive Sentiment: HC Wainwright also raised several near-term quarterly estimates (examples: Q4 2026 to ($0.10) from ($0.11); Q3 2026 to ($0.11) from ($0.12); Q2 2026 to ($0.13) from ($0.14); Q1 2026 to ($0.14) from ($0.15)), suggesting incremental improvement in expected cash burn and operating performance. Article Title
• Neutral Sentiment: Despite upward revisions, the analyst model still projects continued losses across 2026–27 (quarterly losses in the ~$0.10–$0.14 range and FY losses of ($0.48)–($0.50)), so near-term profitability remains distant and dependent on execution or product/catalyst progress. Article Title
• Negative Sentiment: Recent reported results (Feb. 26) missed consensus on both EPS and revenue and showed very large negative margins and ROE, which likely underpins today’s selling pressure despite the bullish price target — investors remain cautious until the company shows consistent revenue growth or margin improvement. Article Title

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.